title: Comment on: "cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective".
authors.affiliation: Grünenthal GmbH, 52099, Aachen, Germany, hiltrud.liedgens@grunenthal.com.
authors.forename: Hiltrud
authors.initials: H
authors.lastname: Liedgens
authors.forename: Rainer
authors.initials: R
authors.lastname: Henske
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D018803:Models, Economic; D010003:Osteoarthritis / Q000188:drug therapy* / Q000191:economics*; D013876:Thiophenes / Q000191:economics*
chemical_list: D013876:Thiophenes
references.citation: Pain Pract. 2010 Sep-Oct;10(5):416-27
references.pmid: 20602712
references.citation: Clin Drug Investig. 2010;30(8):489-505
references.pmid: 20586515
references.citation: Appl Health Econ Health Policy. 2013 Jun;11(3):219-36
references.pmid: 23616247
references.citation: Adv Ther. 2010 Jun;27(6):381-99
references.pmid: 20556560
references.citation: J Opioid Manag. 2012 Nov-Dec;8(6):395-402
references.pmid: 23264317